<div id="readability-page-1"><div><figure></figure>Clinical research company Fortrea Holdings will be reporting earnings this Tuesday before market open. Here’s what to look for.Fortrea missed analysts’ revenue expectations last quarter, reporting revenues of $660.5 million, down 5.2% year on year. It was a softer quarter for the company, with full-year revenue guidance missing analysts’ expectations significantly and a significant miss of analysts’ EPS estimates.Is Fortrea a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.This quarter, the market is expecting Fortrea’s revenue to decline 3.6% year on year, a further deceleration from the 1.6% decrease it recorded in the same quarter last year.<figure></figure>The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Fortrea has missed Wall Street’s revenue estimates multiple times over the last two years.Looking at Fortrea’s peers in the life sciences tools &amp; services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. West Pharmaceutical Services delivered year-on-year revenue growth of 21%, beating analysts’ expectations by 8.4%, and Medpace reported revenues up 26.5%, topping estimates by 1.5%. West Pharmaceutical Services traded up 11.6% following the results while Medpace was down 22.6%.Read our full analysis of West Pharmaceutical Services’s results here and Medpace’s results here.There has been positive sentiment among investors in the life sciences tools &amp; services segment, with share prices up 6% on average over the last month. Fortrea is up 35.2% during the same time and is heading into earnings with an average analyst price target of $12.66 (compared to the current share price of $12.18).ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.</div></div>

FTRE

ARKG

Fortrea Holdings is set to report Q1 earnings on Tuesday, with expectations of a 3.6% year-on-year revenue decline, following a previous miss of $660.5 million in revenue last quarter. Analysts have maintained their estimates, indicating stability ahead of earnings. In contrast, peers like West Pharmaceutical Services and Medpace have shown strong growth. Fortrea's stock has risen 35.2% recently, with an average analyst price target of $12.66, slightly above its current price of $12.18.

Fortrea (FTRE) Q1 Earnings: What To Expect